Trexquant Investment LP Has $206,000 Stake in Kindred Biosciences Inc (KIN)

Trexquant Investment LP grew its stake in Kindred Biosciences Inc (NASDAQ:KIN) by 88.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,228 shares of the biopharmaceutical company’s stock after purchasing an additional 12,325 shares during the period. Trexquant Investment LP owned approximately 0.09% of Kindred Biosciences worth $206,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of Kindred Biosciences in the 2nd quarter valued at approximately $546,000. General American Investors Co. Inc. bought a new stake in shares of Kindred Biosciences in the 3rd quarter valued at approximately $5,232,000. PDT Partners LLC bought a new stake in shares of Kindred Biosciences in the 2nd quarter valued at approximately $254,000. Dimensional Fund Advisors LP grew its stake in shares of Kindred Biosciences by 2.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,369,688 shares of the biopharmaceutical company’s stock valued at $9,656,000 after purchasing an additional 34,735 shares during the period. Finally, TIAA CREF Investment Management LLC bought a new stake in shares of Kindred Biosciences in the 2nd quarter valued at approximately $547,000. Institutional investors own 66.85% of the company’s stock.

A number of equities research analysts recently commented on the company. HC Wainwright set a $10.00 price target on Kindred Biosciences and gave the stock a “buy” rating in a research report on Tuesday, December 5th. B. Riley set a $11.00 price target on Kindred Biosciences and gave the stock a “buy” rating in a research report on Tuesday, December 5th. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research lowered Kindred Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Kindred Biosciences currently has an average rating of “Buy” and a consensus price target of $9.63.

Shares of Kindred Biosciences Inc (KIN) opened at $7.70 on Friday. Kindred Biosciences Inc has a 12-month low of $4.10 and a 12-month high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. equities research analysts predict that Kindred Biosciences Inc will post -1.19 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/10/trexquant-investment-lp-has-206000-stake-in-kindred-biosciences-inc-kin.html.

Kindred Biosciences Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences Inc (NASDAQ:KIN).

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit